ImmunoGen

ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By developing targeted therapies with enhanced anti-tumor activity and good tolerability, we aim to disrupt the progression of cancer and provide more quality time for our patients.